MedTrace Logo

Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors

NCT02993614 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 99999

Last updated 2021-02-18

No results posted yet for this study

Summary

CVD-REAL is a multinational, observational cohort study in patients with type 2 diabetes mellitus evaluating the comparative effectiveness of initiating treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor versus another glucose-lowering drug. This study will compare the risk of all-cause mortality and clinically relevant cardiovascular (CV) outcomes respectively in patients who are new users of SGLT-2 inhibitors with those who are new users of other glucose-lowering drugs. CVD-REAL is aiming to collect data from approximately 4 million patients overall, from twelve countries across three major world regions.

Conditions

  • Diabetes Mellitus Type 2

Sponsors & Collaborators

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-30
Primary Completion
2020-12-17
Completion
2020-12-17

Countries

  • United States
  • Australia
  • Canada
  • Denmark
  • Finland
  • Germany
  • Israel
  • Italy
  • Japan
  • Norway
  • Portugal
  • Singapore
  • South Korea
  • Spain
  • Sweden
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02993614 on ClinicalTrials.gov